pimobendan has been researched along with Pulmonary Hypertension in 6 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " Echocardiography results and invasive measurements of right and left ventricular systolic pressures were compared after 3-week administrations of sildenafil (S group), pimobendan (P group), nicorandil (N group), and their combinations (SP and SPN groups) in male rats with monocrotaline (MCT)-induced pulmonary hypertension (M group) and without this condition (C group)." | 7.81 | Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. ( Fukayama, T; Fukushima, R; Goya, S; Nakata, TM; Tanaka, R; Yoshiyuki, R, 2015) |
| "Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium." | 6.68 | [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema]. ( Fujikane, T; Matsumoto, H; Sasaki, N; Shimizu, T; Takahashi, M; Takahashi, T; Takeda, A; Tsuji, T; Yamazaki, Y, 1997) |
| "Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects." | 5.56 | Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020) |
| " Echocardiography results and invasive measurements of right and left ventricular systolic pressures were compared after 3-week administrations of sildenafil (S group), pimobendan (P group), nicorandil (N group), and their combinations (SP and SPN groups) in male rats with monocrotaline (MCT)-induced pulmonary hypertension (M group) and without this condition (C group)." | 3.81 | Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. ( Fukayama, T; Fukushima, R; Goya, S; Nakata, TM; Tanaka, R; Yoshiyuki, R, 2015) |
| "Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium." | 2.68 | [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema]. ( Fujikane, T; Matsumoto, H; Sasaki, N; Shimizu, T; Takahashi, M; Takahashi, T; Takeda, A; Tsuji, T; Yamazaki, Y, 1997) |
| "Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects." | 1.56 | Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. ( Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020) |
| "In dogs with canine monocytic ehrlichiosis (CME), respiratory signs are uncommon and clinical and radiographic signs of interstitial pneumonia are poorly described." | 1.43 | Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. ( Broens, EM; Dobak, TP; Toom, ML; Valtolina, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Morita, T | 2 |
| Nakamura, K | 1 |
| Osuga, T | 1 |
| Kawamoto, S | 1 |
| Miki, S | 1 |
| Sasaoka, K | 1 |
| Takiguchi, M | 1 |
| Nakata, TM | 1 |
| Tanaka, R | 1 |
| Yoshiyuki, R | 1 |
| Fukayama, T | 1 |
| Goya, S | 1 |
| Fukushima, R | 1 |
| Toom, ML | 1 |
| Dobak, TP | 1 |
| Broens, EM | 1 |
| Valtolina, C | 1 |
| Watanabe, E | 1 |
| Shiga, T | 1 |
| Matsuda, N | 1 |
| Kajimoto, K | 1 |
| Naganuma, M | 1 |
| Kawai, A | 1 |
| Kasanuki, H | 1 |
| Sahara, M | 1 |
| Takahashi, T | 2 |
| Imai, Y | 1 |
| Nakajima, T | 1 |
| Yao, A | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Yamazaki, Y | 1 |
| Matsumoto, H | 1 |
| Takeda, A | 1 |
| Sasaki, N | 1 |
| Takahashi, M | 1 |
| Tsuji, T | 1 |
| Fujikane, T | 1 |
| Shimizu, T | 1 |
1 review available for pimobendan and Pulmonary Hypertension
| Article | Year |
|---|---|
New insights in the treatment strategy for pulmonary arterial hypertension.
Topics: Anticoagulants; Antihypertensive Agents; Calcium Channel Blockers; Diuretics; Drug Therapy, Combinat | 2006 |
1 trial available for pimobendan and Pulmonary Hypertension
| Article | Year |
|---|---|
[Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
Topics: Aged; Blood Pressure; Cardiac Output; Chronic Disease; Humans; Hypertension, Pulmonary; Male; Middle | 1997 |
4 other studies available for pimobendan and Pulmonary Hypertension
| Article | Year |
|---|---|
Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Hypertension, Pulmonary; Infusion | 2020 |
Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; H | 2015 |
Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.
Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte | 2016 |
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension.
Topics: Adult; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Humans; Hypertension, Pulmona | 2003 |